1 week Ago By Defense World Staff
KLP Kapitalforvaltning AS bought a new position in RxSight, Inc. (NASDAQ:RXST – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 6,200 shares of the company’s stock, valued at approximately $213,000.
A number of other institutional investors have also recently bought and sold shares of the business. Quantbot Technologies LP lifted its holdings in shares of RxSight by 31.7% during the 4th quarter.
Quantbot Technologies LP now owns 33,444 shares of the company’s stock worth $1,150,000 after acquiring an additional 8,041 shares during the period. Thrivent Financial for Lutherans lifted its stake in RxSight by 53.6% during the fourth quarter.
Thrivent Financial for Lutherans now owns 352,626 shares of the company’s stock worth $12,124,000 after purchasing an additional 122,989 shares during the period. Telemark Asset Management LLC lifted its stake in RxSight by 6.6% during the fourth quarter.
Telemark Asset Management LLC now owns 321,000 shares of the company’s stock worth $11,036,000 after purchasing an additional 20,000 shares during the period. Swiss National Bank boosted its holdings in RxSight by 2.6% during the fourth quarter.
Swiss National Bank now owns 66,300 shares of the company’s stock valued at $2,279,000 after purchasing an additional 1,700 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in shares of RxSight by 65.7% in the 4th quarter.
AlphaQuest LLC now owns 5,086 shares of the company’s stock valued at $175,000 after purchasing an additional 2,017 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.
Insider Activity at RxSightIn other RxSight news, Director Jesse Anderson Corley bought 1,443 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was bought at an average price of $31.18 per share, for a total transaction of $44,992.
74. Following the transaction, the director now owns 1,443 shares of the company’s stock, valued at approximately $44,992.74.
The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction on Wednesday, March 12th.
The stock was sold at an average price of $25.71, for a total value of $179,970.00.
Following the completion of the transaction, the director now owns 24,793 shares in the company, valued at $637,428.03. This represents a 22.
02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.
36% of the stock is owned by company insiders. RxSight Trading Up 2.2 %Shares of RXST stock opened at $16.
61 on Tuesday. RxSight, Inc. has a 1 year low of $14.
37 and a 1 year high of $66.54. The firm’s 50 day moving average is $27.
80 and its 200-day moving average is $37.53. The firm has a market capitalization of $672.
56 million, a price-to-earnings ratio of -20.01 and a beta of 1.26.
RxSight (NASDAQ:RXST – Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.
10 by ($0.25). The firm had revenue of $40.
21 million for the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative return on equity of 14.
00% and a negative net margin of 23.92%. On average, equities research analysts forecast that RxSight, Inc.
will post -0.7 earnings per share for the current fiscal year. Wall Street Analysts Forecast GrowthSeveral research firms recently commented on RXST.
Stifel Nicolaus cut their target price on RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th.
Wells Fargo & Company cut their price objective on RxSight from $35.00 to $22.00 and set an “equal weight” rating for the company in a report on Thursday, April 3rd.
JPMorgan Chase & Co. reiterated an “underweight” rating and set a $17.00 target price (down previously from $40.
00) on shares of RxSight in a research report on Friday. Bank of America restated an “underperform” rating and issued a $22.00 price target (down from $36.
00) on shares of RxSight in a research report on Thursday, April 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price objective on shares of RxSight in a report on Thursday, April 3rd.
Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, RxSight has a consensus rating of “Hold” and a consensus price target of $43.
78.Check Out Our Latest Analysis on RXSTRxSight Company Profile (Free Report)RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Further ReadingFive stocks we like better than RxSightAre Penny Stocks a Good Fit for Your Portfolio?Options Activity Points to More Volatility for Palantir StockWhat Are Dividend Contenders? Investing in Dividend ContendersNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Why Invest in High-Yield Dividend Stocks?MicroStrategy Sees Insider Buy-Sell Action in Q1.
